Aptus Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Aptus Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$393K	Sell	2,486 -268,233	-99%	-$36.3M	﹤0.01%	858
2026 Q1	$34.6M	Buy	270,719 +268,234	+10,794%	+$33.5M	0.27%	74
2025 Q4	$303K	Buy	2,485 +446	+22%	+$51.1K	﹤0.01%	882
2025 Q3	$204K	Buy	2,039 +1	+0%	+$90	﹤0.01%	976
2025 Q2	$169K	Hold	2,038	–	–	﹤0.01%	980
2025 Q1	$165K	Buy	2,038 +1,572	+337%	+$141K	﹤0.01%	928
2024 Q4	$41.9K	Sell	466 -235	-34%	-$22.8K	﹤0.01%	1131
2024 Q3	$69.3K	Hold	701	–	–	﹤0.01%	892
2024 Q2	$65K	Sell	701 -64	-8%	-$5.74K	﹤0.01%	868
2024 Q1	$72.6K	Buy	765 +2	+0.3%	+$186	﹤0.01%	858
2023 Q4	$68.1K	Sell	763 -1,015	-57%	-$75.4K	﹤0.01%	649
2023 Q3	$130K	Buy	1,778 +313	+21%	+$25K	﹤0.01%	600
2023 Q2	$122K	Sell	1,465 -25	-2%	-$2.09K	﹤0.01%	518
2023 Q1	$114K	Buy	1,490 +794	+114%	+$65.9K	﹤0.01%	510
2022 Q4	$57.8K	Hold	696	–	–	﹤0.01%	583
2022 Q3	$55K	Buy	696 +251	+56%	+$21.2K	﹤0.01%	548
2022 Q2	$33K	Hold	445	–	–	﹤0.01%	503
2022 Q1	$40K	Buy	445 +82	+23%	+$7.57K	﹤0.01%	525
2021 Q4	$41K	Buy	+363	New	+$43.8K	﹤0.01%	437

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Aptus Capital Advisors's XBI Position: Q2 2026 in Review

Aptus Capital Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 99% in Q2 2026, selling an estimated $36.3M and leaving 2,486 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #858.

Aptus Capital Advisors first reported a position in XBI in Q4 2021 and has held it in 19 quarters since. The position peaked at $34.6M in Q1 2026. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Aptus Capital Advisors held 2,486 shares of State Street SPDR S&P Biotech ETF worth $393K as of Q2 2026.
Aptus Capital Advisors sold 268,233 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $36.3M.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #858 holding.
Aptus Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 19 quarters since.
Aptus Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $34.6M in Q1 2026.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.